Immune Checkpoints of the B7 Family. Part 1. General Characteristics and First Representatives: B7-1, B7-2, B7-H1, B7-H2, and B7-DC

Chapoval, Andrei I.; Chapoval, Svetlana P; Shcherbakova, N. S.; Щербаков, Д. Н.

doi:10.1134/s1068162019040101

Cited by 8 publications

(17 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhibitory immune checkpoints substantially regulate T cells' aberrant activation and terminate the AID 22 . The B7 family belongs to immune checkpoints, which their interactions with different receptors can elicit both stimulatory and inhibitory signals 23 . These family members are pivotal health and disease modulators of immune function 24 .…”

Section: Immune Checkpointsmentioning

confidence: 99%

B7 immune checkpoint family members as putative therapeutics in autoimmune disease: An updated overview

et al. 2022

View full text Add to dashboard Cite

Autoimmune diseases, especially among young people in the US, are one of the leading causes of morbidity and death. The immune responses are the fundamental pathogenicity of autoimmune disorders. The equilibrium between stimulatory and inhibitory signals is critical for the stimulation, migration, survival, and T cell‐related immune responses. The B7 family can substantially regulate T cell‐mediated immune responses. Nevertheless, recent breakthroughs in immune checkpoint blockade in cancer immunotherapy have facilitated autoimmune diseases, especially among the prone populations. In the current study, we tried to concisely review the role of the B7 family in regulating immune reactions and the influence of immune checkpoint inhibitors on autoimmunity development.

show abstract

Section: Immune Checkpointsmentioning

confidence: 99%

B7 immune checkpoint family members as putative therapeutics in autoimmune disease: An updated overview

et al. 2022

View full text Add to dashboard Cite

show abstract

“…This is the first signal for T cell activation, whereas a second signal is derived from costimulation where specific costimulatory molecules on APC interact with their receptors on T cells (Figure 1) [6]. The first signal alone does not lead to the immune response to allergen (Figure 1), it rather induces T cell unresponsiveness or "anergy" [6,7].…”

Section: Introductionmentioning

confidence: 99%

“…They can act as costimulators or inhibitors/checkpoints. Currently, there are eleven known representatives of the B7 family, namely: B7-1 (CD80), B7-2 (CD86), B7-H1 (PD-L1, CD274), B7-DC (PDCD1LG2, PD-L2, CD273), B7-H2 (B7RP1, ICOS-L, CD275), B7-H3 (CD276), B7-H4 (B7x, B7S1, Vtcn1), B7-H5 (VISTA, Platelet receptor Gi24, SISP1), B7-H6 (NCR3LG1), B7-H7 (HHLA2), and ILDR2 (the synonyms of IChM names of the B7 family are given in parentheses) [7,8]. Two molecules of B7 family proteins [9], B7-1 and B7-2, are the best characterized costimulators [7,8].…”

Section: Introductionmentioning

confidence: 99%

Costimulation in Allergic Asthma: The Roles of B7 and Semaphorin Molecules

Chapoval¹,

Chapoval²

2022

Recent Advances in Asthma Research and Treatments

View full text Add to dashboard Cite

It is well established that allergic asthma is T cell-driven disease where CD4+ T cells of Th2 phenotype play a critical role in disease initiation and maintenance. There are several critical steps in the induction of Th2 type immune response to the allergen. The first critical step is the antigen processing and presentation of allergen-derived peptides in the context of specific major histocompatibility Class II (MHCII) molecules by antigen-presenting cells (APC). Recognition of this complex by T cell receptor (TCR) and interaction of costimulatory ligands with corresponding receptors represents the second step in T cell activation. As the third part of optimal T cell differentiation, proliferation, and expansion, several cytokines, integrins, and chemokines get involved in the fine-tuning of DC-T cell interaction and activation. Multiple recent evidences point to the selected members of B7 and semaphorin families as important checkpoints providing a fine-tuning regulation of immune response. In this book chapter, we discuss the properties of costimulatory molecules and address their roles in allergic asthma.

show abstract

“…Receptors for the B7 family ligands expressed on the surface of T lymphocytes can deliver both stimulating and inhibitory signals that regulate the immune response [1,2]. Inhibitory receptor CTLA-4 (CD152) interact with ligands B7-1 (CD80) and B7-2 (CD86), while PD-1 (CD279) receptor binds B7-H1 (PD-L1, CD274) and B7-DC (PD-L2, CD273).…”

Section: Introductionmentioning

confidence: 99%

“…Inhibitory receptor CTLA-4 (CD152) interact with ligands B7-1 (CD80) and B7-2 (CD86), while PD-1 (CD279) receptor binds B7-H1 (PD-L1, CD274) and B7-DC (PD-L2, CD273). These molecules are also termed as immunological checkpoints [1,2]. Injections of monoclonal antibodies (mAb) blocking immunological checkpoints, such as CTLA-4, PD-1, and PD-L1, enhance antitumor immunity and lead to tumor rejection [3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Peptide Blocking CTLA-4 and B7-1 Interaction

et al. 2021

View full text Add to dashboard Cite

Discovery of the B7 family immune checkpoints such as CTLA-4 (CD152), PD-1 (CD279), as well as their ligands B7-1 (CD80), B7-2 (CD86), B7-H1 (PD-L1, CD274), and B7-DC (PD-L2, CD273), has opened new possibilities for cancer immunotherapy using monoclonal antibodies (mAb). The blockade of inhibitory receptors (CTLA-4 and PD-1) with specific mAb results in the activation of cancer patients’ T lymphocytes and tumor rejection. However, the use of mAb in clinics has several limitations including side effects and cost of treatment. The development of new low-molecular compounds that block immune checkpoints’ functional activity can help to overcome some of these limitations. In this paper, we describe a synthetic peptide (p344) containing 14 amino acids that specifically interact with CTLA-4 protein. A 3D computer model suggests that this peptide binds to the 99MYPPPY104 loop of CTLA-4 protein and potentially blocks the contact of CTLA-4 receptor with B7-1 ligand. Experimental data confirm the peptide-specific interaction with CTLA-4 and its ability to partially block CTLA-4/B7-1 binding. The identified synthetic peptide can be used for the development of novel immune checkpoint inhibitors that can block CTLA-4 functional activity for cancer immunotherapy.

show abstract

Immune Checkpoints of the B7 Family. Part 1. General Characteristics and First Representatives: B7-1, B7-2, B7-H1, B7-H2, and B7-DC

Cited by 8 publications

References 138 publications

B7 immune checkpoint family members as putative therapeutics in autoimmune disease: An updated overview

B7 immune checkpoint family members as putative therapeutics in autoimmune disease: An updated overview

Costimulation in Allergic Asthma: The Roles of B7 and Semaphorin Molecules

Peptide Blocking CTLA-4 and B7-1 Interaction

Contact Info

Product

Resources

About